Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 4 May 2007:
Vol. 316. no. 5825, pp. 750 - 754
DOI: 10.1126/science.1141736

Reports

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Erik D. Roberson,1,2* Kimberly Scearce-Levie,1,2 Jorge J. Palop,1,2 Fengrong Yan,1 Irene H. Cheng,1,2 Tiffany Wu,1 Hilary Gerstein,1 Gui-Qiu Yu,1 Lennart Mucke1,2*

Many potential treatments for Alzheimer's disease target amyloid-ß peptides (Aß), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Aß-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Aß levels. Tau reduction also protected both transgenic and nontransgenic mice against excitotoxicity. Thus, tau reduction can block Aß- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions.

1 Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
2 Department of Neurology, University of California, San Francisco, CA 94158, USA.

* To whom correspondence should be addressed. E-mail: eroberson{at}gladstone.ucsf.edu (E.D.R.); lmucke{at}gladstone.ucsf.edu (L.M.)

Read the Full Text



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study.
G. D. Silverberg, M. Mayo, T. Saul, J. Fellmann, J. Carvalho, and D. McGuire (2008)
Neurology 71, 202-209
   Abstract »    Full Text »    PDF »
Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase C{gamma}1, Grb2, and Src Family Kinases.
C. H. Reynolds, C. J. Garwood, S. Wray, C. Price, S. Kellie, T. Perera, M. Zvelebil, A. Yang, P. W. Sheppard, I. M. Varndell, et al. (2008)
J. Biol. Chem. 283, 18177-18186
   Abstract »    Full Text »    PDF »
Distinct mechanisms of impairment in cognitive ageing and Alzheimer's disease.
M. Mapstone, K. Dickerson, and C. J. Duffy (2008)
Brain 131, 1618-1629
   Abstract »    Full Text »    PDF »
Co-Localization of Amyloid Beta and Tau Pathology in Alzheimer's Disease Synaptosomes.
J. A. Fein, S. Sokolow, C. A. Miller, H. V. Vinters, F. Yang, G. M. Cole, and K. H. Gylys (2008)
Am. J. Pathol. 172, 1683-1692
   Abstract »    Full Text »    PDF »
Enkephalin Elevations Contribute to Neuronal and Behavioral Impairments in a Transgenic Mouse Model of Alzheimer's Disease.
W. J. Meilandt, G.-Q. Yu, J. Chin, E. D. Roberson, J. J. Palop, T. Wu, K. Scearce-Levie, and L. Mucke (2008)
J. Neurosci. 28, 5007-5017
   Abstract »    Full Text »    PDF »
A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease.
Y. Matsuoka, Y. Jouroukhin, A. J. Gray, L. Ma, C. Hirata-Fukae, H.-F. Li, L. Feng, L. Lecanu, B. R. Walker, E. Planel, et al. (2008)
J. Pharmacol. Exp. Ther. 325, 146-153
   Abstract »    Full Text »    PDF »
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity.
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al. (2008)
Brain 131, 651-664
   Abstract »    Full Text »    PDF »
The Potential for -Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy.
M.-M. Mocanu, A. Nissen, K. Eckermann, I. Khlistunova, J. Biernat, D. Drexler, O. Petrova, K. Schonig, H. Bujard, E. Mandelkow, et al. (2008)
J. Neurosci. 28, 737-748
   Abstract »    Full Text »    PDF »
The beta-Propensity of Tau Determines Aggregation and Synaptic Loss in Inducible Mouse Models of Tauopathy.
K. Eckermann, M.-M. Mocanu, I. Khlistunova, J. Biernat, A. Nissen, A. Hofmann, K. Schonig, H. Bujard, A. Haemisch, E. Mandelkow, et al. (2007)
J. Biol. Chem. 282, 31755-31765
   Abstract »    Full Text »    PDF »
A Tale about Tau.
K. H. Ashe (2007)
N. Engl. J. Med. 357, 933-935
   Full Text »    PDF »



ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)